Ducentis Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $428M

  • Investors
  • 1

Ducentis General Information

Description

Developer of novel therapies designed to provide treatment for inflammation and autoimmune diseases. The company offers an axis that is distinct from conventional immunomodulators which exploit blockade mechanisms to inhibit the action of pro-inflammatory molecules which transmits a deactivating signal to activated immune cells and thus acts to promote tolerance and restore immune homeostasis.

Contact Information

Website
www.ducentisbio.com
Formerly Known As
Tripos Biopharma, Deucentis Limited
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 264 Banbury Road
  • Oxfordshire
  • Oxford OX2 7DY
  • England, United Kingdom
+44 01993
Primary Industry
Biotechnology
Acquirer
Arcutis Biotherapeutics
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 264 Banbury Road
  • Oxfordshire
  • Oxford OX2 7DY
  • England, United Kingdom
+44 01993

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ducentis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 28-Dec-2022 $428M Completed Pre-Clinical Trials
6. Later Stage VC (Series A) Cancelled Pre-Clinical Trials
5. Later Stage VC 12-Oct-2022 Completed Generating Revenue
4. Later Stage VC 14-Jun-2019 Completed Pre-Clinical Trials
3. Later Stage VC 03-Apr-2018 Completed Startup
2. Early Stage VC 17-Mar-2016 $56.7K $181K Completed Startup
1. Early Stage VC 13-Jul-2015 $125K $125K Completed Startup
To view Ducentis’s complete valuation and funding history, request access »

Ducentis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
A Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 222,223 $0.000112 $0.2 $0.2 1x $0.2 2.92%
Ordinary 357,143 $0.000112 $0.16 $0.16 1x $0.16 4.7%
To view Ducentis’s complete cap table history, request access »

Ducentis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapies designed to provide treatment for inflammation and autoimmune diseases. The company offers
Biotechnology
Oxford, United Kingdom
3 As of 2024

Abingdon, United Kingdom
 

Indianapolis, IN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ducentis Competitors (2)

One of Ducentis’s 2 competitors is Pathios Therapeutics, a Venture Capital-Backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pathios Therapeutics Venture Capital-Backed Abingdon, United Kingdom
Eli Lilly Corporation Indianapolis, IN
You’re viewing 2 of 2 competitors. Get the full list »

Ducentis Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

Ducentis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202418600-D0 Composition and method of using mutated cd200 fusion protein Pending 18-Dec-2024
GB-202320145-D0 Composition and method of using mutated cd200 fusion protein Inactive 29-Dec-2023
GB-202306711-D0 Novel proteins Inactive 05-May-2023
GB-202218501-D0 Mutated cd200 proteins and methods of use therof Pending 08-Dec-2022
GB-2626300-A Mutated cd200 proteins and methods of use therof Pending 08-Dec-2022 C07K14/70596
To view Ducentis’s complete patent history, request access »

Ducentis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ducentis Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
LifeArc Ventures Venture Capital Minority
Oxford Technology Management Venture Capital Minority
To view Ducentis’s complete investors history, request access »

Ready to get started?

Request a free trial

Ducentis FAQs

  • When was Ducentis founded?

    Ducentis was founded in 2012.

  • Where is Ducentis headquartered?

    Ducentis is headquartered in Oxford, United Kingdom.

  • What is the size of Ducentis?

    Ducentis has 3 total employees.

  • What industry is Ducentis in?

    Ducentis’s primary industry is Biotechnology.

  • Is Ducentis a private or public company?

    Ducentis is a Private company.

  • What is the current valuation of Ducentis?

    The current valuation of Ducentis is .

  • What is Ducentis’s current revenue?

    The current revenue for Ducentis is .

  • How much funding has Ducentis raised over time?

    Ducentis has raised $7.47M.

  • Who are Ducentis’s investors?

    LifeArc Ventures and Oxford Technology Management have invested in Ducentis.

  • Who are Ducentis’s competitors?

    Pathios Therapeutics and Eli Lilly are competitors of Ducentis.

  • When was Ducentis acquired?

    Ducentis was acquired on 28-Dec-2022.

  • Who acquired Ducentis?

    Ducentis was acquired by Arcutis Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »